How Does Avamys Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Avamys Works
- Active Ingredient: Fluticasone furoate, a synthetic trifluorinated glucocorticoid with high affinity for the glucocorticoid receptor.
- Primary Action: Reduces inflammation in the nasal passages by suppressing pro‑inflammatory cytokines, eosinophil infiltration, and mast cell mediators.
- Onset & Duration: Some effect within 8–24 hours; full benefit after several days; once‑daily dosing provides 24‑hour control.
- Metabolism: Extensively metabolised by CYP3A4 in the liver to inactive metabolites; minimal systemic absorption (<1%).
- Usage: Licensed for adults and children (6+ years) with seasonal or perennial allergic rhinitis.
Avamys (fluticasone furoate) is a nasal spray that delivers a potent corticosteroid directly to the nasal mucosa. It targets the underlying allergic inflammation to relieve symptoms like congestion, sneezing, and itchy nose without significant systemic exposure.
Important Medical Advice
Seek immediate medical help if you experience difficulty breathing, swelling of the face or throat, or severe skin rash after using Avamys – these could be signs of a serious allergic reaction. Long‑term use in children requires regular height monitoring; report any visual disturbances (possible glaucoma/cataracts) to your doctor promptly.
Chemical Composition & Molecular Structure
Avamys nasal spray contains the active substance fluticasone furoate, a novel glucocorticoid designed for high topical potency. Each delivered spray provides 27.5 micrograms of fluticasone furoate. The excipients ensure stability, uniform dispersion, and preservation: glucose anhydrous, dispersible cellulose, polysorbate 80, benzalkonium chloride (8.25 µg per spray), disodium edetate, and purified water.
Structural Details
6α,9α‑difluoro‑17α‑[(2‑furanylcarbonyl)oxy]‑11β‑hydroxy‑16α‑methyl‑3‑oxoandrosta‑1,4‑diene‑17β‑carbothioate, S‑(fluoromethyl) ester
A synthetic corticosteroid with a furoate ester at the 17α position, which enhances lipophilicity and glucocorticoid receptor binding affinity. The trifluoromethylthioester group contributes to metabolic stability and prolonged tissue retention.
Quaternary ammonium preservative
Acts as an antimicrobial preservative. Present at 0.015% w/v, it may cause nasal irritation in sensitive individuals with prolonged use.
Key Pharmaceutical Properties
| Property | Fluticasone furoate |
|---|---|
| Molecular weight | 538.6 g/mol |
| Lipophilicity (logP) | ~3.6 |
| Protein binding | >99% |
| Glucocorticoid receptor affinity (Kd) | ~0.5 nM (high) |
| Aqueous solubility | Very low (suspension formulation) |
| pKa (phenolic group) | ~10.5 (not ionised at physiological pH) |
🗒️ Pharmaceutical insight: The furoate ester markedly increases lipophilicity, promoting rapid uptake into nasal mucosal cells and prolonged retention – the basis for once‑daily dosing.
Mechanism of Action: How Avamys Works
Fluticasone furoate is a full agonist at the human glucocorticoid receptor. After intranasal administration, it diffuses across cell membranes of epithelial and inflammatory cells (eosinophils, mast cells, macrophages) and binds to cytoplasmic glucocorticoid receptors. The activated receptor complex translocates to the nucleus, where it:
- Transrepression: Suppresses pro‑inflammatory transcription factors (NF‑κB, AP‑1), reducing the production of cytokines (IL‑4, IL‑5, IL‑13), chemokines, and adhesion molecules.
- Transactivation: Increases expression of anti‑inflammatory proteins such as lipocortin‑1 (annexin A1) and IκBα, further dampening the inflammatory cascade.
- Non‑genomic effects: Rapid vasoconstriction and reduction of mucosal oedema may occur within hours via membrane‑bound receptor interactions.
The overall effect is a decrease in eosinophil infiltration, mast cell stabilisation, reduced mucus secretion, and alleviation of nasal itching, sneezing, congestion, and rhinorrhoea.
| Target cell | Effect of fluticasone furoate |
|---|---|
| Eosinophils | Apoptosis induction, reduced survival |
| Mast cells | Inhibition of histamine and leukotriene release |
| Epithelial cells | Decreased chemokine secretion, tight junction stabilisation |
| Th2 lymphocytes | Suppression of IL‑4, IL‑5, IL‑13 synthesis |
🗒️ Physiological insight: The high receptor affinity and lipophilicity mean that once bound, fluticasone furoate dissociates slowly, providing prolonged anti‑inflammatory activity even when plasma concentrations are undetectable.
Absorption & Distribution (Pharmacokinetics)
After nasal spray administration, a fraction of the dose is deposited in the nasal passages and absorbed across the mucosa. The majority of the swallowed portion undergoes extensive first‑pass metabolism, resulting in negligible systemic bioavailability (<1% on average).
Pulmonary / nasal absorption
Peak plasma concentrations are extremely low (typically <10 pg/mL after recommended doses) and occur 1–2 hours post‑dose. Due to the low concentrations, standard pharmacokinetic parameters are difficult to characterise accurately.
Distribution
Fluticasone furoate is highly protein‑bound (>99%) and has a large volume of distribution (~300 L), indicating extensive tissue distribution. It crosses the placenta and appears in breast milk in trace amounts; however, systemic exposure from nasal use is minimal.
Onset of action: Some symptom relief may be noticed within 8–24 hours after the first dose, but maximum benefit usually requires several days of regular use (up to 2 weeks in some individuals).
Metabolic Effects & Elimination
Metabolism: Fluticasone furoate is rapidly and extensively metabolised in the liver by the cytochrome P450 enzyme CYP3A4 to a single major metabolite – the 17β‑carboxylic acid derivative – which has <0.1% of the receptor affinity of the parent drug. No other active metabolites are formed.
Elimination: The metabolites are excreted primarily in the faeces (≈90%) via bile, with the remainder eliminated in urine. The terminal half‑life of fluticasone furoate is approximately 15 hours, supporting once‑daily dosing.
Drug interactions: Concomitant use with potent CYP3A4 inhibitors (e.g., ritonavir, cobicistat, ketoconazole) may increase systemic fluticasone furoate exposure, raising the risk of systemic corticosteroid effects. Caution and monitoring are advised.
⚠️ Metabolic caution: Although systemic absorption is minimal, patients with severe hepatic impairment may have reduced clearance; however, no dose adjustment is considered necessary based on current data.
Clinical Efficacy in Allergic Rhinitis
Avamys is indicated for the symptomatic treatment of seasonal (hayfever) and perennial allergic rhinitis in adults and children aged 6 years and over. Pivotal clinical trials demonstrated:
- Nasal symptom relief: Significant reduction in total nasal symptom score (congestion, itching, sneezing, rhinorrhoea) compared to placebo, evident within 8–24 hours and sustained over 24 hours with once‑daily use.
- Ocular symptom improvement: Fluticasone furoate also reduces eye symptoms (itching, watering, redness) in patients with allergic rhinitis, likely due to drainage through the nasolacrimal duct and systemic absorption of minute amounts.
- Health‑related quality of life: Improvements in sleep, daily activities, and work/school performance were reported in both seasonal and perennial allergic rhinitis.
- Paediatric data: In children aged 6–11 years, the 55 µg/day (1 spray each nostril) dose effectively controlled symptoms with minimal systemic exposure; growth monitoring is recommended for long‑term use.
Long‑term studies (up to 12 months) showed maintained efficacy with no evidence of tachyphylaxis. The intranasal corticosteroid is generally well tolerated; the most common adverse event is mild epistaxis, especially with use beyond 6 weeks.
Avamys FAQs
How long does Avamys take to start working?
Some people feel relief within 8–24 hours of the first dose, but it may take several days of regular use to experience the full benefit. Consistency is key.
Can Avamys be used in children?
Yes, Avamys is licensed for children aged 6 years and older. The usual dose is 1 spray in each nostril once daily, increased to 2 sprays if needed under medical supervision.
What are the most common side effects of Avamys?
The most frequent side effects are minor nosebleeds (especially if used for more than 6 weeks), nasal ulceration, headache, and mild throat irritation.
Is Avamys safe during pregnancy?
There is limited data; use only if clearly needed and prescribed by your doctor. Uncontrolled allergic rhinitis can also affect pregnancy, so discuss risks and benefits.
Does Avamys contain steroids?
Yes, it contains the corticosteroid fluticasone furoate, but it acts locally in the nose with minimal absorption into the rest of the body.
Need Avamys with Expert Guidance?
If you suffer from hayfever or year‑round allergies, a UK‑registered doctor can assess your symptoms and prescribe Avamys online if appropriate.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Allergy ConsultationRelated Avamys Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co‑founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up‑to‑date.
Medical Doctor
Dr. Feroz is a GMC‑registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co‑founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 15 March 2026
Next Review: 15 September 2026
Published on: 15 March 2026
Last Updated: 15 March 2026